RNA 8-K 2026-11-02

Atrium Therapeutics, Inc. (RNA) 8-K dated 2026-11-02 — accession 0001193125-26-442601.

Atrium Therapeutics, Inc. (RNA) is a biotechnology company listed on NASDAQ.

Atrium Therapeutics, Inc. filed a 8-K on 2026-11-02. Accession 0001193125-26-442601.

This 8-K covers: Reg FD disclosure (Item 7.01), Other events (Item 8.01), Exhibits (Item 9.01). SEC EDGAR holds the official filing and its exhibits.

Latest reported RNA revenue for 2025-12-31 was $18.8M. Net income was -$684.6M. Revenue was up 72.1% from 2024-12-31 to 2025-12-31. RNA currently screens at market cap $217.5M.

Not investment advice. The RNA SEC hub lists recent forms. The stock page is the research view.